# reload+after+2024-01-19 22:44:35.208012
address1§2223 Avenida De La Playa
address2§Suite 105
city§La Jolla
state§CA
zip§92037
country§United States
phone§858 412 5302
website§https://equilliumbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
fullTimeEmployees§45
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Daniel Mark Bradbury', 'age': 62, 'title': 'Executive Chairman', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 158000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bruce D. Steel C.F.A.', 'age': 57, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 796950, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine  Zedelmayer M.B.A., P.M.P.', 'age': 53, 'title': 'Senior VP & COO', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 561750, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Connelly Ph.D.', 'age': 41, 'title': 'Chief Scientific Officer & Director', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 579600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason A. Keyes', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Moore', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew  Ritter Ph.D.', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joel M. Rothman', 'age': 54, 'title': 'Chief Development Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Maple  Fung M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.118
priceToSalesTrailing12Months§0.6756607
currency§USD
dateShortInterest§1702598400
forwardEps§-0.66
exchange§NCM
quoteType§EQUITY
shortName§Equillium, Inc.
longName§Equillium, Inc.
firstTradeDateEpochUtc§1539351000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2dcbad74-77fd-3056-9e8b-8198f173bd47
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§8.0
targetMeanPrice§8.0
targetMedianPrice§8.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§1.836
grossMargins§1.0
ebitdaMargins§-0.21474001
trailingPegRatio§None
